Epigenetic modifications to cytosine are known to alter transcriptional states and deregulate gene expression in cancer, embryonic development, and most recently in neurodegeneration. To test the hypothesis that global levels of cytosine modification are altered throughout the progression of Alzheimer's disease, 5-methylcytosine (5-mC) and 5-hydroxymethylcytosine (5-hmC) were quantified using gas chromatography/mass spectrometry (GC/MS) and stable labeled internal standards of cytosine, 5-mC, and 5-hmC. Cytosine modifications were quantified in DNA extracted from tissue specimens of four brain regions (cerebellum, inferior parietal lobe, superior and middle temporal gyrus, and hippocampus/parahippocampal gyrus) of cognitively normal control (NC) subjects and subjects with mild cognitive impairment (MCI), preclinical Alzheimer's disease (PCAD), late onset Alzheimer's disease, frontotemporal lobar degeneration (FTLD) and dementia with Lewy bodies (DLB). Repeated measures analyses of the data show significant alterations in 5-mC and 5-hmC in early stages of Alzheimer's disease (PCAD and MCI), as well as FTLD and DLB subjects, across multiple regions of the brain. These data suggest alterations in epigenetic regulation of genes may play an early role in the progression of AD as well as other types of neurodegeneration. (Figure presented.).
|Number of pages||12|
|Journal||Journal of Neurochemistry|
|State||Published - Feb 1 2017|
Bibliographical noteFunding Information:
This work was supported by National Institute of Health grants 5P01-AG05119 and P30-AG028383, as well as a grant from Alltech Biotechnology. The authors thank Dr Peter Nelson, Dr Steven Scheff, Ms. Sonya Anderson, and Ms. Ela Patel from the UK-ADC Clinical and Neuropathology Cores, and Mr. Timothy Shannon from the Data Management and Statistics Core for subject data, and Ms. Paula Thomason for editorial assistance. The authors report no conflict of interest in the research or data described in this article. All experiments were conducted in compliance with the ARRIVE guidelines.
© 2016 International Society for Neurochemistry
- Alzheimer's disease
ASJC Scopus subject areas
- Cellular and Molecular Neuroscience